HAIXI PHARMA's stock plummeted 8.35% during intraday trading on Monday, marking a significant decline for the pharmaceutical company.

The sharp drop is primarily attributed to ongoing selling pressure following the expiration of the stock's post-IPO lock-up period. The six-month lock-up recently ended, releasing approximately 1.9817 million shares held by cornerstone investors, representing 2.52% of the company's total share capital. This has created substantial selling pressure in the market as these investors are now able to trade their holdings.

Additionally, the stock is experiencing a continued correction from its historical highs. HAIXI PHARMA had nearly doubled in value over the preceding month, reaching a record high of 302.4 HKD before plunging over 25% in a single session. Despite a brief two-day rebound, the overall pattern remains one of high-level consolidation and retreat as the stock corrects from its recent rapid appreciation.